Accessibility StatementSkip Navigation NEW YORK, Dec. 2, 2025 /PRNewswire/ -- What to do next: To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/? case_id=46109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf o ...

记者丨庞华玮 编辑丨包芳鸣 随着资本市场结构性行情深化，蓄势已久的A股定增市场在2025年迎来公募基金的深度参与。截至12月2日，2025年内已有33家基金 公司参与定增，获配总金额高达173亿元，相比2024年全年大幅增长140%。 公募定增资金高度聚焦半导体、人工智能、创新药等领 域，赚钱效应显著。 头部机构领衔聚焦硬科技 今年以来，公募参与定增的规模与热情均呈爆发式增长。 来自格上基金的数据显示， 2025年以来，33家公募基金公司通过公募基金参与定增投资，获配的总金额已高达173亿元，相较去年 全年的72亿元，增长超过100亿元，增幅达140%。 "今年公募基金对于定增的态度明显升温。"前海开源基金首席经济学家杨德龙在接受21世纪经济报道记者采访时指出，"随着市场行 情特别是成长板块的走强，参与定增能锁定优质公司的中长期成长机会，吸引力显著提升。" 在这场定增盛宴中，头部公募机构扮演了"主力军"角色。 从获配金额看，易方达基金以36.87亿元的规模一马当先，广发基金、富国基金和中欧基金紧随其后，获配金额分别为22.88亿元、 15.29亿元和14.63亿元。 汇添富、工银瑞信、兴证全球和鹏华等基金公司 ...

Group 1 - The webinar is hosted by Jasper Therapeutics, featuring key executives including the CEO, acting CMO, and a professor from Charite in Berlin [2] - The event includes a presentation of slides that are accessible via a webinar link and posted on the Investor Relations website [2] - Forward-looking statements will be made during the event, based on estimates and assumptions regarding future events [3]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Question-and-Answer SessionWell, so why don't we just start off with a little bit of an overview on Sana. I know you recently streamlined our pipeline to focus on SC451, which is your T1D islet cell product. And also SG293, which is your in vivo CAR T product. Just talk a little bit about that decision and what Sana looks like going forward?Steven HarrPresident, CEO & Director Sure. First of all, thanks, everybody, for joining us, both in the room and online. And I think you guys know we'll be making forwar ...

Arcus Biosciences (NYSE:RCUS) FY Conference December 02, 2025 04:40 PM ET Speaker1All right. Well, good afternoon, everybody. Welcome. Thank you so much to Arcus Management for joining us. We've got Terry and Jen here with us. I can't wait to go through all the exciting data and all the updates coming soon. But let's start with a minute or two from you. What are you excited about heading into 2026? Where are the strategic focuses, and where should we be paying our attention?Speaker2Sure. So I think number o ...

Bicara Therapeutics (NasdaqGM:BCAX) FY Conference December 02, 2025 04:30 PM ET Speaker1Perfect. Let's get started. Welcome, everybody, to the next session. My name is Kelsey Goodwin. I am one of the analysts here at Piper Sandler. Our next session, we have Bicara. We have the President and COO, Ryan Cohlhepp. Thanks for joining us.Speaker0Thank you.Speaker1Let's start with a quick summary of Bicara, where we stand heading into year-end and 2026.Speaker0Yeah. So for those of you who are not familiar with Bi ...

Upstream Bio (NasdaqGS:UPB) FY Conference December 02, 2025 04:30 PM ET Speaker1Good afternoon, everyone. Welcome to the Piper Sandler Healthcare Conference. My name is Yaz Rahimi. I'm a senior biotech analyst here at Piper Sandler. Really excited to have Upstream Bio and Rand here with me. Lots to cover over the next 25 minutes. I think 2025 was a big year with the chronic sinusitis readout, and 2026 is going to be even more exciting with the verekitug asthma data upcoming here in Q1. I think maybe the fir ...

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Cepton, Inc. (NASDAQ:CPTN) and MoonLake Immunotherapeutics (NASDAQ:MLTX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. MoonLake Immunotherapeutics (NASDAQ:MLTX) Class Period: Ma ...

Madrigal Pharmaceuticals (NasdaqGS:MDGL) FY Conference December 02, 2025 04:15 PM ET Company ParticipantsBill Sibold - CEOMardi Dier - CFOConference Call ParticipantsMike DiFiore - AnalystMike DiFioreLet's get started.Bill SiboldLet's get started.Mike DiFioreBut welcome, everybody. Those of you who don't know me, I'm Mike DiFiore. I'm one of the biotech analysts covering Madrigal and Evercore. But pleasure to have the management team from Madrigal here. Bill, Mardi, welcome. Thanks so much for making it dow ...